Biomarker plan
There is a company that is developing gene therapy for Retina market and Cystic fibrosis called 4DMT. What would its Biomarker plan look like and what would the translational person do at the company?
Sometimes it is clear what is needed though specific execution steps and assays can be challenging. The devil is in the details but here are the broad steps:
- Biomarker current 4DMT status: across 4D-150 and 4D-710, evaluating current assays, sample collection procedures, analytical validation status, and decision-making utility.
- Target engagement: Link vector delivery to transgene expression and target engagement : a) 4D-150: transgene’s protein expression, VEGF-A/C suppression, retinal fluid dynamics.
b) 4D-710: CFTR expression, CFTR functional activity, sweat chloride and airway physiology. - Immunogenicity measurement: pre-existing neutralizing antibodies, anti-capsid antibodies, T-cell responses, cytokine profiling, and transgene-specific (therapeutic protein) immune monitoring.
- PK/PD and biomarker-response models to identify relationships between dose, expression levels, target engagement, immune responses, and clinical outcomes.
- Standardize biospecimen and data strategies such as sample collection across studies to ensure longitudinal assessment of transduction, expression, immune response, and durability.
- In addition: a) Translational review with Clinical Development, Research, Regulatory, and Biostatistics to ensure biomarkers directly inform development decisions and regulatory interactions and b) evaluate current technologies to improve sensitivity c) Operational: Personnel, outsourcing, vendors, negotiation of contracts.
Company website: https://4dmoleculartherapeutics.com/
